Zobrazeno 1 - 10 of 53 pro vyhledávání: '"Jaume Aguado"'
1
Cardiovascular events and all‐cause mortality in patients with chronic obstructive pulmonary disease using olodaterol and other long‐acting beta2‐agonists
Autor: Cristina Rebordosa, Dóra Körmendiné Farkas, Jukka Montonen, Kristina Laugesen, Florian Voss, Jaume Aguado, Ulrich Bothner, Kenneth J. Rothman, Kristina Zint, Daniel Mines, Vera Ehrenstein
Publikováno v: Rebordosa, C, Farkas, D K, Montonen, J, Laugesen, K, Voss, F, Aguado, J, Bothner, U, Rothman, K J, Zint, K, Mines, D & Ehrenstein, V 2022, ' Cardiovascular Events and All-Cause Mortality in Patients With Chronic Obstructive Pulmonary Disease Using Olodaterol and Other Long-Acting Beta2-Agonists ', Pharmacoepidemiology and Drug Safety, vol. 31, no. 8, pp. 827-839 . https://doi.org/10.1002/pds.5432
Purpose: We examined the effect of olodaterol on the risk of myocardial ischaemia, cardiac arrhythmia, and all-cause mortality compared with use of other long-acting beta2-agonists (LABAs). Channelling bias was also explored. Methods: This Danish pop
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab499cebc8e93730a07024ba7b871ffa
https://doi.org/10.1002/pds.5432
Zobrazit plný text záznamu
2
No Evidence of Off-label Use of Olodaterol and Indacaterol in Denmark, France, and the Netherlands: A Drug Utilization Study
Autor: Ulrich Bothner, Kristina Laugesen, Jetty A. Overbeek, Vera Ehrenstein, Jaume Aguado, Laura Wallace, E. Houben, Jukka Montonen, Cristina Rebordosa, Joelle Asmar, Alicia Gilsenan
Publikováno v: Scientific Reports, Vol 10, Iss 1, Pp 1-9 (2020)
Scientific Reports
Rebordosa, C, Houben, E, Laugesen, K, Bothner, U, Montonen, J, Aguado, J, Overbeek, J A, Ehrenstein, V, Asmar, J, Wallace, L & Gilsenan, A W 2020, ' No Evidence of Off-label Use of Olodaterol and Indacaterol in Denmark, France, and the Netherlands : A Drug Utilization Study ', Scientific Reports, vol. 10, no. 1, 586 . https://doi.org/10.1038/s41598-019-57397-5
To characterize the use of olodaterol and indacaterol in clinical practice and to quantify the off-label use in asthma. Drug utilization study of new users of olodaterol or indacaterol between 2014 and 2017 in the PHARMO Database Network in the Nethe
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f440cc349c1a27cd1a944aea15c6c7cd
http://link.springer.com/article/10.1038/s41598-019-57397-5
Zobrazit plný text záznamu
3
Risk Assessment of Acute Myocardial Infarction and Stroke Associated with Long-Acting Muscarinic Antagonists, Alone or in Combination, versus Long-Acting beta2-Agonists
Autor: Cristina Rebordosa, Estel Plana, Annalisa Rubino, Jaume Aguado, David Martinez, Alejhandra Lei, Sami Daoud, Nuria Saigi-Morgui, Susana Perez-Gutthann, Elena Rivero-Ferrer
Publikováno v: International journal of chronic obstructive pulmonary disease. 17
Cristina Rebordosa,1 Estel Plana,2 Annalisa Rubino,3 Jaume Aguado,2 David Martinez,2 Alejhandra Lei,4 Sami Daoud,5 Nuria Saigi-Morgui,1 Susana Perez-Gutthann,1 Elena Rivero-Ferrer1 1Department of Epidemiology and Risk Management, RTI Health Solutions
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::065e7923673e05a2f74748dacf8571e9
https://pubmed.ncbi.nlm.nih.gov/35941901
Zobrazit plný text záznamu
4
Use of aclidinium did not increase the risk of death in a noninterventional cohort study in the Clinical Practice Research Datalink (CPRD), United Kingdom
Autor: Esther García-Gil, Alejhandra Lei, Steven Thomas, Estel Plana, Jaume Aguado, Susana Perez-Gutthann, Jordi Castellsague, Javier Nuevo, Ana Frances, Cristina Rebordosa
Publikováno v: Respiratory Medicine. 152:37-43
Aclidinium bromide is an inhaled long-acting muscarinic antagonist (LAMA). Although the initial potential increased cardiovascular and mortality risk among users of tiotropium has been ruled out by several observational studies, and clinical trials,
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8993258e5dd4d4faaf1894d8840ad75
https://doi.org/10.1016/j.rmed.2019.04.018
Zobrazit plný text záznamu
6
Characteristics of new users of aclidinium, aclidinium/formoterol, and other COPD medications in three European countries
Autor: Cristina Rebordosa, Anna Julia Witzleb, Nina Sahlertz Kristiansen, Susana Perez-Gutthann, Sami Z. Daoud, Estel Plana, Anton Pottegård, Elena Rivero-Ferrer, Tania Schink, Jaume Aguado, Morten Olesen, Annalisa Rubino, Alejhandra Lei, Nuria Saigi
Publikováno v: Epidemiology.
Background: Use of aclidinium bromide (AB) and aclidinium/formoterol (AB/FF) in the real world is not fully characterized in Europe. Aim: To describe characteristics of new users of AB, AB/FF, and other COPD medications in the United Kingdom (UK), De
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::df9c8bd77f840e59f69ae55fb510dbb3
https://doi.org/10.1183/13993003.congress-2020.2072
Zobrazit plný text záznamu
7
GOLD assessment of COPD severity in the Clinical Practice Research Datalink (CPRD)
Autor: Cristina Rebordosa, Jordi Castellsague, Susana Perez-Gutthann, Esther García-Gil, Estel Plana, Steven Thomas, Jaume Aguado
Publikováno v: Pharmacoepidemiology and Drug Safety. 28:126-133
Purpose To evaluate availability of spirometry and symptom data in the Clinical Practice Research Datalink (United Kingdom) to assess COPD severity using the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2016 definition and comparing
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7593027706a00172fe599f291aa49b6a
https://doi.org/10.1002/pds.4448
Zobrazit plný text záznamu
8
Cost-Utility of Group Acceptance and Commitment Therapy for Fibromyalgia Versus Recommended Drugs: An Economic Analysis Alongside a 6-Month Randomized Controlled Trial Conducted in Spain (EFFIGACT Study)
Autor: Lance M. McCracken, Jaume Aguado, Albert Feliu-Soler, María Teresa Peñarrubia-María, Antoni Serrano-Blanco, Francesco D'Amico, Martin Knapp, Javier García-Campayo, Juan V. Luciano
Publikováno v: Luciano, J V, D’Amico, F, Feliu-Soler, A, McCracken, L M, Aguado, J, Peñarrubia-María, M T, Knapp, M, Serrano-Blanco, A & García-Campayo, J 2017, ' Cost-utility of Group Acceptance and Commitment Therapy for Fibromyalgia versus recommended drugs: An economic analysis alongside a 6-month randomised controlled trial conducted in Spain (EFFIGACT study) ', JOURNAL OF PAIN . https://doi.org/10.1016/j.jpain.2017.03.001
The aim of this study was to analyze the cost utility of a group-based form of acceptance and commitment therapy (GACT) in patients with fibromyalgia (FM) compared with patients receiving recommended pharmacological treatment (RPT) or on a waiting li
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f390cc18056723f09f47ddab1b9fe09a
https://doi.org/10.1016/j.jpain.2017.03.001
Zobrazit plný text záznamu
9
Risk of acute liver injury in agomelatine and other antidepressant users in four european countries: a cohort and nested case–control study using automated health data sources
Autor: Lena Brandt, Rosa Morros, Emmanuelle Jacquot, Tania Schink, Jesper Hallas, Gabriel Perlemuter, Maria Giner-Soriano, Antje Timmer, Nicolas Deltour, Bruno Falissard, Jordi Castellsague, Anton Pottegård, Manel Pladevall-Vila, Jordi Cortés, Miguel Cainzos-Achirica, Maja Hellfritzsch, Beatriz Poblador-Plou, David Hägg, Alexandra Prados-Torres, Jaume Aguado, Johan Reutfors, Susana Perez-Gutthann, Joan Forns, Tammo Reinders
Publikováno v: Scientia
UPCommons. Portal del coneixement obert de la UPC
Universitat Politècnica de Catalunya (UPC)
Recercat. Dipósit de la Recerca de Catalunya
instname
CNS drugs, 33(4):383-395
CNS Drugs
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Pladevall-Vila, M, Pottegård, A, Schink, T, Reutfors, J, Morros, R, Poblador-Plou, B, Timmer, A, Forns, J, Hellfritzsch, M, Reinders, T, Hägg, D, Giner-Soriano, M, Prados-Torres, A, Cainzos-Achirica, M, Hallas, J, Brandt, L, Cortés, J, Aguado, J, Perlemuter, G, Falissard, B, Castellsagué, J, Jacquot, E, Deltour, N & Perez-Gutthann, S 2019, ' Risk of Acute Liver Injury in Agomelatine and Other Antidepressant Users in Four European Countries : A Cohort and Nested Case-Control Study Using Automated Health Data Sources ', CNS Drugs, vol. 33, no. 4, pp. 383-395 . https://doi.org/10.1007/s40263-019-00611-9
Acute liver injury; Antidepressants; Case-control Lesió hepàtica aguda; Antidepressius; Control de casos Lesión hepática aguda; Antidepresivos; Control de casos Background Agomelatine is a melatonin receptor agonist and serotonin 5-HT2C receptor
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::936d1cae613f8e5d0bc01d45b6566e6e
http://scientiasalut.gencat.cat/handle/123456789/3836
Zobrazit plný text záznamu
10
Baseline Predictors for Success Following Strategy-Based Cognitive Remediation Group Training in Schizophrenia
Autor: Aida Farreny, Judith Usall, Jaume Aguado, Susana Ochoa, Silvia Corbera, Elena Huerta-Ramos
Publikováno v: Journal of Nervous & Mental Disease. 204:585-589
Our aim was to examine predictive variables associated with the improvement in cognitive, clinical, and functional outcomes after outpatient participation in REPYFLEC strategy-based Cognitive Remediation (CR) group training. In addition, we investiga
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ffb28c0e22e9d807081e18ab776e2599
https://doi.org/10.1097/nmd.0000000000000509
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje